Prognostic and predictive factors of lenvatinib in patients with hepatocellular carcinoma
Not Applicable
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000036625
- Lead Sponsor
- Kitasato University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) Cases with a history of hypersensitivity to the ingredients of this drug 2) Patients who have been treated with other molecule-targeted drugs 3) Women who are pregnant, have a possibility of becoming pregnant, fall within 28 days postpartum, or breastfeeding. A man who wants a partner's pregnancy. 4) A case in which a mental illness or mental disorder that interferes with daily life is included and it is judged that participation in research is difficult 5) Cases judged as inappropriate for this study by the principal investigator
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method